<SEC-DOCUMENT>0001558370-25-007065.txt : 20250509
<SEC-HEADER>0001558370-25-007065.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509071306
ACCESSION NUMBER:		0001558370-25-007065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		25928367

	BUSINESS ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>qure-20250509x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/9/2025 5:46:10 AM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: f6f3ddf6-a277-42ce-ad49-20c6f9ebe005 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:qure="http://www.uniqure.com/20250509" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityCentralIndexKey" id="Tc_bpT8YWymVkycx4xZ0IAxUg_1_1">0001590560</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityTaxIdentificationNumber" id="Hidden_avu0_Ref3UCtAOlHLxF5FQ">00-0000000</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:AmendmentFlag" id="Narr_cd82Xnou-E-anXk_5Ru_ug">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="qure-20250509.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ff00ff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_102cec41_9342_4b6f_84a6_d242687b0ead"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:DocumentType" id="Narr_rw_BBUv9S0e6wOP3pcDWKw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_dhZL-hcjHEi5kyZD_GPrKw"><b style="font-weight:bold;">May 9, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityRegistrantName" id="Narr_-E_LnEWGq0azDKFDRfCq5g"><b style="font-weight:bold;">uniQure N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_680ab967_cb20_437c_904f_ebc8e7a9f90a"></a><a id="Tc_hPChdYopdkGzJMbkDRGuOw_0_0"></a><a id="Tc_UDkqtPMlxkWpaX739Kwqdw_1_0"></a><a id="Tc_YWbXukVO5kq4wpgxJdzLYQ_1_2"></a><a id="Tc_mCGnWNvtS0CJu2Jfhz6YGw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:32.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The </b><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Narr_ooXHMgZbL0CfmEiDa42vkg"><b style="font-weight:bold;">Netherlands</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:32.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityFileNumber" id="Tc_IZHlb3DjH0W-ON8-r2RZqA_0_2"><b style="font-weight:bold;">001-36294</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:32.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_avu0_Ref3UCtAOlHLxF5FQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">N/A</b></span></p></td></tr><tr><td style="vertical-align:top;width:32.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other<br/>Jurisdiction of Incorporation)</p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:32.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission<br/>File Number)</p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:32.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer<br/>Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt 0pt 0pt 27.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityAddressAddressLine1" id="Narr_SHOkPm8-tk2Lbnm9aZBOGw"><b style="font-weight:bold;">Paasheuvelweg 25a</b></ix:nonNumeric><b style="font-weight:bold;">,</b><br/><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityAddressPostalZipCode" id="Narr_IG3gFsK-nE648J85rMGSLQ"><b style="font-weight:bold;">1105 BP</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:EntityAddressCityOrTown" id="Narr_Sx2-i4zG9EGvJWSV8VPklw"><b style="font-weight:bold;">Amsterdam</b></ix:nonNumeric><b style="font-weight:bold;">, The </b><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_DAgPaPuDjkWwMJHWvYqD7g"><b style="font-weight:bold;">Netherlands</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt 0pt 0pt 27.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 0pt 27.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:CityAreaCode" id="Narr_Os15_nahOUKB0T1T2BxEyA"><b style="font-weight:bold;">+31</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:LocalPhoneNumber" id="Narr_9ooBiv0mfkGJ1M9lXqBscQ"><b style="font-weight:bold;">20-566-7394</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_rogAJoM0rUm3fstQ7W8m5w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_5YVVZHF4wE2JL0PS8iJrFQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_95sikW-K5E6lN8I7zAi2eg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_lQMLiaxsD0WS-S5e9j0ijA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_be53e1d3_4903_402d_afa5_5be4a69d56aa"></a><a id="Tc_qXjd7sApqkiol9ScKvPMUg_1_0"></a><a id="Tc_l0w9e4scSUeCL4dNUBqh9A_1_2"></a><a id="Tc_7MQpcL9FRkKGCUGFIqMX7A_1_4"></a><a id="Tc_2s2xRsmRAE6mpmb_q1TXdg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class:</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered:</b></p></td></tr><tr><td style="vertical-align:top;width:37.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:Security12bTitle" id="Tc_ov_aaMEWuUynfaeQOg6W_g_2_0">Ordinary Shares, par value &#8364;0.05 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:1.03%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:21.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" name="dei:TradingSymbol" id="Tc_9k62nLkurEK9FgY6gmve4Q_2_2">QURE</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:39.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_oakbG8c8wUOLEKjSJguU2w">The Nasdaq Stock Market LLC</ix:nonNumeric><br/>The Nasdaq Global Select Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_3gIZ0-AFCE-jo1dOsNOYqQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b3de497b_3833_4f36_b015_5257873259b3"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Item 2.02</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 9, 2025, uniQure N.V. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;) issued a press release announcing its financial results for the quarter ended March 31, 2025 and highlighting Company progress. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:159.5pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2730c94b_1702_4fa0_a807_1c4d3831005b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;"> Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d) Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="qure-20250509xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release of uniQure N.V. dated May 9, 2025</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded with the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5500a047_afa0_4d24_aff3_37721ecd9c23"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">UNIQURE N.V. </b></p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 9, 2025</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ JEANNETTE POTTS</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeannette Potts</p></td></tr><tr><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal and Compliance Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>qure-20250509xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/9/2025 05:46:08 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><img src="qure-20250509xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.22pt;width:136.8pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:15pt;font-weight:bold;">uniQure Announces First Quarter 2025 Financial Results and</b><b style="font-size:15pt;font-weight:bold;"><br></b><b style="font-size:15pt;font-weight:bold;">Highlights of Recent Company Progress</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ AMT-130 granted Breakthrough Therapy designation by FDA~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated,</i><i style="font-style:italic;"><br></i><i style="font-style:italic;">with no treatment-related serious adverse events ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-</i><i style="font-style:italic;"><br></i><i style="font-style:italic;">130; regulatory update expected in the second quarter of 2025 ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies &amp; Diagnostics Development</i><i style="font-style:italic;"><br></i><i style="font-style:italic;">Symposium on May 29, 2025 ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31</i><i style="font-style:italic;"><br></i><i style="font-style:italic;">2025 expected to fund operations into second half of 2027 ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">~ uniQure to host inaugural earnings call at 8:30 a.m. ET ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Lexington, MA and Amsterdam, the Netherlands, </b>May 9, 2025 <font style="font-family:'Arial Narrow';">&#8212;</font> uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2025 and highlighted recent progress across its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Arial Narrow';">&#8220;</font>We continued to have constructive interactions with the U.S. Food and Drug Administration (FDA) in the first &#160;and second quarters of 2025, enabling us to further advance AMT-130 towards a planned Biologics License Application (BLA) submission,<font style="font-family:'Arial Narrow';">&#8221;</font> said Matt Kapusta, chief executive officer of uniQure. <font style="font-family:'Arial Narrow';">&#8220;</font>The recently granted Breakthrough Therapy designation is a significant milestone and underscores the FDA<font style="font-family:'Arial Narrow';">&#8217;</font>s continued engagement with AMT-130 as a potential disease-modifying treatment for Huntington<font style="font-family:'Arial Narrow';">&#8217;</font>s disease. We expect to provide a regulatory update in the second quarter, including guidance on the potential timing of our BLA submission for AMT-130, and anticipate sharing new clinical data from our AMT-130 Phase I/II trials in the third quarter. As we prepare for potential commercialization, we remain committed to making financially disciplined investments.<font style="font-family:'Arial Narrow';">&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mr. Kapusta continued, <font style="font-family:'Arial Narrow';">&#8220;</font>In addition to AMT-130, it<font style="font-family:'Arial Narrow';">&#8217;</font>s important to highlight the continued progress of our broader pipeline of investigational gene therapies. We look forward to sharing initial data from the first patient treated with AMT-260 for refractory mesial temporal lobe epilepsy later this quarter, and we remain on track to present initial data from our AMT-191 study in Fabry disease in the second half of the year. With our strong financial position, we believe that we are well-resourced to execute across our pipeline and deliver meaningful value to patients and shareholders alike.<font style="font-family:'Arial Narrow';">&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Company Developments and Updates</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Advancing AMT-130 Toward Accelerated Approval for Huntington</i><i style="font-family:'Arial Narrow';font-size:10pt;font-style:italic;font-weight:normal;">&#8217;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">s disease</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April 2025, the FDA granted Breakthrough Therapy designation to AMT-130 based on clinical evidence from Phase I/II trials showing the potential for slowing progression of Huntington</font><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s disease. The designation followed a November 2024 multidisciplinary meeting with the FDA</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">during which key elements of an Accelerated Approval pathway for AMT-130 were discussed and aligned.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In March 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of a planned BLA submission. An additional Type B meeting focused on the pivotal statistical analysis plan was held in the second quarter of 2025. The Company expects to provide a regulatory update, including the potential timing of a BLA submission, after the receipt of official meeting minutes.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2025, the Company completed enrollment of all 12 patients in the third cohort of the Phase I/II study. Patients were blinded and randomized to receive either the high (n=6) or low dose (n=6) of AMT-130 in conjunction with an immunosuppression regimen.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">Key observations include:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">AMT-130 was generally well-tolerated at both dose levels;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">No treatment-related serious adverse events were reported;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Three serious adverse events related to immunosuppression (mania, infection, and fever) were observed; all resolved fully with supportive care and;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Perioperative changes in CSF NfL were consistent with previously reported observations, reinforcing their association with the surgical administration.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company plans to review these data with outside advisors and does not anticipate any impact on the potential timing of a BLA submission.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission.</font><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The update will include follow-up data on all patients treated with AMT-130 in the first two cohorts, including three years of follow-up data on 24 treated patients.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Advancing additional clinical programs to proof-of-concept</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (mTLE)</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company continues to screen patients across 12 clinical sites, with plans to activate additional centers in the second half of the year. The Company expects to present initial safety and exploratory efficacy data from the first treated patient at the Epilepsy Therapies &amp; Diagnostics Development Symposium on Thursday, May 29, 2025.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">AMT-191 for the treatment of Fabry disease </i><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In February 2025, the Company announced a favorable recommendation from the independent data monitoring committee (IDMC) following a review of safety data from the first two patients treated in the Phase I/IIa study. The Company has treated a total of four patients in the first dose cohort. The Company plans to present initial data from the study in the second half of 2025</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">.</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS)</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In January 2025, the Company announced a favorable recommendation from the IDMC based on the review of initial safety data from the first study cohort in the Phase I/II EPISOD1 study. The Company has completed enrollment in a second dose cohort and expects to initiate enrollment in the third dose</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">cohort in the third quarter of 2025. The Company expects to present initial data from the study in the first half of 2026.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Strong financial position</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the first quarter of 2025, the Company completed a public offering of 5.1 million ordinary shares, including the full exercise of the underwriters</font><font style="font-family:'Arial Narrow';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> overallotment option, at a public offering price of $17.00 per share for net proceeds of approximately $80.5 million after deducting underwriting discounts and commissions and offering expenses.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash position:</b> As of March 31, 2025, the Company held cash, cash equivalents and current investment securities of $409.0 million, compared to $367.5 million as of December 31, 2024. The increase in cash was primarily related to net proceeds of $80.5 million from the follow-on offering in January and February 2025. Based on the Company<font style="font-family:'Arial Narrow';">&#8217;</font>s current operating plan, including the planned U.S. launch of AMT-130, the Company expects cash, cash equivalents and current investment securities will be sufficient to fund operations into the second half of 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenues:</b> Revenue for the three months ended March 31, 2025 was $1.6 million, compared to $8.5 million in the same period in 2024. The decrease of $6.9 million in revenue resulted from a $0.4 million increase in license revenue, a decrease of $3.3 million from collaboration revenue, and a decrease of $4.0 million from contract manufacturing of HEMGENIX<sup style="font-family:'Arial Narrow';font-size:7.5pt;vertical-align:top;">&#174;</sup><sup style="font-size:7.5pt;vertical-align:top;"> </sup>for CSL Behring. Following the divestment of the Lexington facility in July 2024, revenue from contract manufacturing is recorded net of cost within other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cost of contract manufacturing revenues: </b>Cost of contract manufacturing revenues were nil for the three months ended March 31, 2025, compared to $9.1 million for the same period in 2024. Following the divestment of the Lexington facility in July 2024, cost of contract manufacturing is recorded net of revenue within other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">R&amp;D expenses:</b> Research and development expenses were $36.1 million for the three months ended March 31, 2025, compared to $40.7 million during the same period in 2024. The $4.6 million decrease was related to a decrease of $7.7 million in employee-related expenses, a decrease of $2.5 million in facility expenses and a $1.1 million decrease in costs related to preclinical supplies. This was offset by a net increase of $7.1 million in external program spend and $1.1 million higher expenses related to an increase in the fair value of contingent consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SG&amp;A expenses: </b>Selling, general and administrative expenses were $10.9 million for the three months ended March 31, 2025, compared to $13.9 million during the same period in 2024. The $3.0 million decrease was primarily related to a $2.2 million decrease in employee-related expenses and a $0.3 million decrease in intellectual property fees compared to the prior year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other income:</b> Other income was $8.3 million for the three months ended March 31, 2025, compared to $1.4 million during the same period in 2024. The increase was primarily related to a one-time gain of $6.0 million related to the sale of critical reagents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other expense</b>: Other expense was $2.0 million for the three months ended March 31, 2025, compared to $0.2 million during the same period in 2024. The increase was primarily related to $1.4 million of non-cash expense recognized to amortize the right to purchase HEMGENIX&#174; from Genezen on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other non-operating items, net:</b> Other non-operating items, net was an expense of $3.8 million for the three months ended March 31, 2025, compared to an expense of $10.7 million for the same period in 2024. The $6.9 million decrease in other non-operating items, net was primarily related to a decrease in interest income of $2.4 million, a reduction of interest expense of $1.0 million due to the $50.0 million repayment of Hercules debt in July 2024, and an increase in net foreign currency gains of $8.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss:</b> The net loss for the three months ending March 31, 2025, was $43.6 million, or $0.82 basic and diluted loss per ordinary share, compared to a $65.6 million net loss for the same period in 2024, or $1.36 basic and diluted loss per ordinary share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Investor Conference Call and Webcast Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">uniQure management will host an investor conference call and webcast today,<font style="font-family:'Arial Narrow';">&#160;</font>Friday, May 9 at<font style="font-family:'Arial Narrow';">&#160;</font>8:30 a.m. ET. The event will be webcast under the Events &amp; Presentations section of uniQure<font style="font-family:'Arial Narrow';">&#8217;</font>s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. &#160;Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. &#160;If you are joining the conference call, please dial in 15 minutes before the start time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About uniQure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">uniQure is delivering on the promise of gene therapy <font style="font-family:'Arial Narrow';">&#8211;</font> single treatments with potentially curative results. The approvals of uniQure<font style="font-family:'Arial Narrow';">&#8217;</font>s gene therapy for hemophilia B <font style="font-family:'Arial Narrow';">&#8211;</font> an historic achievement based on more than a decade of research and clinical development <font style="font-family:'Arial Narrow';">&#8211;</font> represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington&#39;s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.<font style="font-family:'Arial Narrow';">&#160;</font>www.uniQure.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">uniQure Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">anticipate,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">believe,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">could,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">establish,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">estimate,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">expect,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">goal,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">intend,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">look forward to</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;">, </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">may,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">plan,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">potential,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">predict,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">project,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">seek,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">should,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">will,</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">would</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> and similar expressions. Forward-looking statements are based on management&#39;s beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s cash runway and its ability to fund its operations into the second half of 2027; the outcome of regulatory interactions with respect to the AMT-130 program, FDA</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s support for the program and the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s plans to provide further regulatory updates, including timing of its planned BLA submission; whether AMT-130 continues to be well tolerated when dosed with immunosuppression and the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s review of data from the third cohort of AMT-130; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s commercialization plans; and the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s plans for further clinical updates and plans to announce additional interim data in its AMT-130, AMT-260, AMT-191 and AMT-162 programs. The Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s programs; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s ability to continue to build and maintain the Company infrastructure and personnel needed to achieve its goals; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">therapies; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s ability to obtain, maintain and protect intellectual property; and the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s ability to fund its operations and to raise additional capital as needed. These risks and uncertainties are more fully described under the heading </i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">Risk Factors</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;"> in the Company</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8217;</i><i style="font-style:italic;">s periodic filings with the U.S. Securities &amp; Exchange Commission (</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8220;</i><i style="font-style:italic;">SEC</i><i style="font-family:'Arial Narrow';font-style:italic;">&#8221;</i><i style="font-style:italic;">), including its Annual Report on Form 10-K filed with the SEC on February 27, 2025 and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">uniQure Contacts:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:108pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR INVESTORS:</b></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;">FOR MEDIA:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Chiara Russo</b></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;">Tom Malone</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Direct: 617-306-9137<font style="display:inline-block;width:21.08pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Direct: 339-970-7558</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mobile: 617-306-9137<font style="display:inline-block;width:17.17pt;"></font> <font style="display:inline-block;width:33.5pt;"></font><font style="display:inline-block;width:36pt;"></font>Mobile:339-223-8541</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.russo@uniQure.com<font style="display:inline-block;width:18.25pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>t.malone@uniQure.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED BALANCE SHEETS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 217,229</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 158,930</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current investment securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 191,782</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 208,591</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,522</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,881</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,420</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,281</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets and receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 10,468</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,606</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 435,421</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 390,289</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 18,081</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 20,424</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,273</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 27,464</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,466</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,647</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 71,992</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 71,043</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 23,351</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 22,414</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,390</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,856</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,429</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,399</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 169,982</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 166,247</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 605,403</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 556,536</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,268</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,227</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 27,344</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 29,225</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,698</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,601</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 36,310</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 40,053</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 51,592</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 51,324</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liability from royalty financing agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 446,660</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 434,930</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 10,906</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,136</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,560</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 10,860</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liability, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,338</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,043</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,351</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,942</font></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 535,407</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 523,235</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 571,717</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 563,288</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shareholders&#39; equity / (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders&#39; equity / (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 33,686</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (6,752)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#39; equity / (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 605,403</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 556,536</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended&#160;March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenues</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,567</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,485</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of license revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (197)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (150)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of contract manufacturing revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,076)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (36,140)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (40,692)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (10,908)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13,937)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (47,245)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (63,855)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 8,306</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,376</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,959)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (234)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (39,331)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,228)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-operating items, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,810)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (10,734)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,141)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (64,962)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (496)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (656)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,637)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (65,618)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per ordinary share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.82)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1.36)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per ordinary share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 53,110,580</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48,384,510</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>qure-20250509xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 qure-20250509xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !6 0H# 2(  A$! Q$!_\0
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MKM*L3P".?E%$LTP\<!_:+O[/EYMM;>@HY7B98_\ LU)>TYN7?2_J>G45\^?
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M _B3_P E \3_ /81N/\ T8:^Y?A7_P DV\+_ /8-@_\ 0!7PU\2?^2@>)_\
ML(W'_H9K[E^%?_)-?"__ &#8/_0!4\$_\C7&_/\ ]*%QQ_R*<!\O_24?&WQX
M)/Q?\49.?])4?^0UKZ4_994+\(+(@8S=7!/_ 'V:^<_VAK5K3XQ^(@R[?,>*
M5?<&)>?YU] _LFWL=S\+&MU<&2VOYE=<_=SAA^AKGX:]SBG%1EO^\_\ 2DSK
MXF]_A7"2CM^[_P#26>U5\ _&;_DK'BS_ *_W_D*^E_&G[2NA>$O'5OH0A>\M
MHI#'J-[&>+9NP4?Q8_B].V37RS\2=6@U[X@^(M1MI!+;7-]*\4BGAUS@$>Q
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MN>![9KZ=UK]ECP1J5C%#9V]SI4R,I-Q!.SLZ@\@AB1R,\CI7B?[*G_)6XO\
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M%+10 4F*6B@ I,4M% !1110 4444 %%%% !1110 4E+10 F*,"EHH *2EHH
M**** "BBB@ HHHH 2C%+10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>qure-20250509.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2025 5:46:16 AM-->
<!--Modified on: 5/9/2025 5:46:16 AM-->
<xsd:schema targetNamespace="http://www.uniqure.com/20250509" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:qure="http://www.uniqure.com/20250509" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20250509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20250509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>qure-20250509_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2025 5:46:16 AM-->
<!--Modified on: 5/9/2025 5:46:16 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>qure-20250509_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/9/2025 5:46:16 AM-->
<!--Modified on: 5/9/2025 5:46:16 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="qure-20250509.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638823663764448289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638823663764448289" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638823663764448289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638823663764448289" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638823663764448289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638823663764448289" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638823663764448289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638823663764448289" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638823663764458274" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638823663764458274" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638823663764458274" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638823663764458274" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638823663764458274" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638823663764458274" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638823663764458274" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638823663764458274" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638823663764458274" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638823663764458274" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638823663764458274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638823663764458274" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638823663764468255" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638823663764468255" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCountry_638823663764468255" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638823663764468255" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638823663764468255" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638823663764468255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638823663764468255" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638823663764478267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638823663764478267" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">uniQure N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Paasheuvelweg 25a<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Amsterdam<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">1105 BP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20-566-7394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value &#8364;0.05 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QURE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">NL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *,YJ5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *,YJ5H1V]9![@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( *,YJ5H<.&7J/P$  #P"   /
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MDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "C.:E:)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ HSFI6F60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( *,YJ5H1V]9![@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ HSFI6APX9>H_ 0  / (   \
M     ( !:!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *,YJ5HD'INB
MK0   /@!   :              "  =01  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( *,YJ5IED'F2&0$  ,\#   3
M  "  ;D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(   ,4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="qure-20250509x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>qure-20250509.xsd</File>
    <File>qure-20250509_lab.xml</File>
    <File>qure-20250509_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="qure-20250509x8k.htm">qure-20250509x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "qure-20250509x8k.htm": {
   "nsprefix": "qure",
   "nsuri": "http://www.uniqure.com/20250509",
   "dts": {
    "schema": {
     "local": [
      "qure-20250509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "qure-20250509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qure-20250509_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "qure-20250509x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qure-20250509x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qure-20250509x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-25-007065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-007065-xbrl.zip
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MX9]BF!"H6$R]'4WVM8(<#W-Q]3"Q.G7E8K88OG,7%\PE-@G%M7&.0^ $Y]T
M9T'U\*\B;_6X+EM@W[EYSQSDW 1J0_1(6+Y!P#^OU[G%>C&X'F:^D;\R-5O
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M#BHMT!\6K)'9VLV8SF;&Q)[S!\P%.?4\/P8]#<DG)P@C\D=, W@*X1KVR?%
MAQWJDN\LC-TH)-2S.1L?\:1WH^#]8W_S.[QQ\8.0^&-X.)).SOP96(L%^1;X
MDX"%X?/)T_TS[2S3@J^'3@2_MN#;_P.+=%UKF@TR":B'=NL#V*\?T33PXPE8
MO2D#&5L0FX7P,(H*348+\NGCZ?^]>^N4E:0+#TP/2$)(QRR"P5.PK>/ GY%H
MZ@0VL?RI'T3(K6]3&C)R\?;B FX8VPL23OW;9$8LN+GCQ4!&Y),1(Q/FP6RX
M[H+<,M<%<^O"6Y@R@T_%SC$)P;KO*NYH/)]$Z$+0!=6X\02FX)SY,<BT?</
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M%2U@?%^-9\L")V42<(UL#A\GN&GF@VGQ>;6(VFS#R.N+CU_.WLC G,=1*IT
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MVP!,VC!U2X9"$.J+4:V'P->JJ5:GTS4Z9K=:_1C4F1BN0[D2\9,PCA_'ZI7
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M=^[#D@IKN<I"8YIR1L0O'-,T&\:@D?M!%=474XUI#BNF3:-I5J6=WQE\!T]
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M^6]'OKV ?Z;1S'W__U!+ 0(4 Q0    ( *,YJ5J[ZNPTC@,  -,,   1
M          "  0    !Q=7)E+3(P,C4P-3 Y+GAS9%!+ 0(4 Q0    ( *,Y
MJ5I<O]=G7P4  +L[   5              "  ;T#  !Q=7)E+3(P,C4P-3 Y
M7VQA8BYX;6Q02P$"% ,4    " "C.:E:4%3W!)$$   B)P  %0
M    @ %/"0  <75R92TR,#(U,#4P.5]P<F4N>&UL4$L! A0#%     @ HSFI
M6E!K?">-%   "H\  !0              ( !$PX  '%U<F4M,C R-3 U,#EX
M.&LN:'1M4$L! A0#%     @ HSFI6L TA,K6*0  V3," !@
M ( !TB(  '%U<F4M,C R-3 U,#EX97@Y.60Q+FAT;5!+!08     !0 % $T!
(  #>3      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>qure-20250509x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qure-20250509.xsd" xlink:type="simple"/>
    <context id="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Tc_bpT8YWymVkycx4xZ0IAxUg_1_1">0001590560</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Hidden_avu0_Ref3UCtAOlHLxF5FQ">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_cd82Xnou-E-anXk_5Ru_ug">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_rw_BBUv9S0e6wOP3pcDWKw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_dhZL-hcjHEi5kyZD_GPrKw">2025-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_-E_LnEWGq0azDKFDRfCq5g">uniQure N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_ooXHMgZbL0CfmEiDa42vkg">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Tc_IZHlb3DjH0W-ON8-r2RZqA_0_2">001-36294</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_SHOkPm8-tk2Lbnm9aZBOGw">Paasheuvelweg 25a</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_IG3gFsK-nE648J85rMGSLQ">1105 BP</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_Sx2-i4zG9EGvJWSV8VPklw">Amsterdam</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_DAgPaPuDjkWwMJHWvYqD7g">NL</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_Os15_nahOUKB0T1T2BxEyA">+31</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_9ooBiv0mfkGJ1M9lXqBscQ">20-566-7394</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_rogAJoM0rUm3fstQ7W8m5w">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_5YVVZHF4wE2JL0PS8iJrFQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_95sikW-K5E6lN8I7zAi2eg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_lQMLiaxsD0WS-S5e9j0ijA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Tc_ov_aaMEWuUynfaeQOg6W_g_2_0">Ordinary Shares, par value &#x20ac;0.05 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Tc_9k62nLkurEK9FgY6gmve4Q_2_2">QURE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_oakbG8c8wUOLEKjSJguU2w">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_9_2025_To_5_9_2025_L5OZnMUF00aPlWQluaiygA"
      id="Narr_3gIZ0-AFCE-jo1dOsNOYqQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
